Biogen: Multiple Sclerosis, Relapsing-Remitting trials

The registry lists 80 Multiple Sclerosis, Relapsing-Remitting studies with Biogen as lead sponsor. 0 are open to participants now and 31 have results posted.

Phase 1 4Phase 2 9Phase 3 25Phase 4 22No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisTerminatedNCT05265728Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsTerminatedNCT03870763Phase 3Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompletedNCT03689972Phase 3Results posted
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2CompletedNCT03093324Phase 3Results posted
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From NatalizumabTerminatedNCT02881567Phase 3Results posted
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1CompletedNCT02634307Phase 3Results posted
• Plegridy Satisfaction Study in ParticipantsCompletedNCT02587065Phase 4Results posted
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02555215Phase 3Results posted
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).CompletedNCT02525874Phase 3Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT02283853Phase 3Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Treatment Interruption of NatalizumabCompletedNCT01071083Phase 2Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisCompletedNCT00451451Phase 3Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00390221Phase 2Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsCompletedNCT06127095
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
• A Study for Tysabri Participant PreferenceCompletedNCT05304520
• Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsCompletedNCT04832399
• Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraCompletedNCT04756687
• Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support ProgramCompletedNCT04655222
• Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPCompletedNCT04221191
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT03958877Phase 3
• A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisCompletedNCT03347370
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
• Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With PlegridyCompletedNCT03091569Phase 4
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT02776072
• Clinical Disease Activity With Long Term Natalizumab TreatmentCompletedNCT02677077
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012CompletedNCT02579681Phase 3
• Brimonidine Tartrate for the Treatment of Injection Related ErythemaWithdrawnNCT02568111Phase 4
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple SclerosisWithdrawnNCT02472938Phase 4
• Tecfidera and the Gut MicrobiotaCompletedNCT02471560Phase 4
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)TerminatedNCT02323269
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)CompletedNCT02159573
• Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateWithdrawnNCT02090348Phase 4
• Tolerability and Quality of Life Study in Participants Who Switched to Avonex PenCompletedNCT02076841
• Ireland Natalizumab (TYSABRI) Observational ProgramCompletedNCT01943526
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesCompletedNCT01930708Phase 4
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• PK and PD Study of Natalizumab in Pediatric Subjects With RRMSCompletedNCT01884935Phase 1
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01838668Phase 3
• Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsTerminatedNCT01706107
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
• Safety Study of BIIB033 in Subjects With Multiple SclerosisCompletedNCT01244139Phase 1
• Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSCompletedNCT00884481
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSCompletedNCT00837785Phase 1
• A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder FunctionCompletedNCT00818038
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• COMPliance With Avonex® PS in Patients With Relapsing-Remitting MSCompletedNCT00675883
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
• Tysabri Observational ProgramCompletedNCT00493298
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
• Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT00492765Phase 4
• GER-009-06-AVX Early Therapy in Multiple SclerosisCompletedNCT00492570
• Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
• Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MSCompletedNCT00168766Phase 4
• AVONEX® Combination Trial - "ACT"CompletedNCT00112034Phase 4
• Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisCompletedNCT00030966Phase 3
• Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisCompletedNCT00027300Phase 3